Industry · Scientific research and development
Research and experimental development on natural sciences and engineering.
Companies and filings in the Research and experimental development on natural sciences and engineering industry, within the Professional, scientific and technical activities sector.
628
Companies
20
New filings
Latest filings
Live feed| Company | Document | Date | Actions |
|---|---|---|---|
|
Regulatory Filings
Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications
|
May 28 | ||
|
Regulatory Filings
Launch of brain health study with Oura
|
May 28 | ||
|
Share Issue/Capital Change
PREDICT: AVVENUTO DEPOSITO DELLO STATUTO AGGIORNATO A SEGUITO DELLA VARIAZIONE DELLA COMPOSIZIONE DEL CAPITALE SOCIALE POST-ANNULLAMENTO DELLA SECONDA TRANCHE DI PAS
|
May 28 | ||
|
Declaration of Voting Results & Voting Rights Announcements
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2026
|
May 28 | ||
|
Annual Report
Annual Report and Accounts to 31 December 2025
|
May 28 | ||
|
Transaction in Own Shares
Next Day Disclosure Return - Changes in issued shares and share buybacks
|
May 28 | ||
|
Board/Management Information
第六届董事会第十八次会议决议公告
|
May 28 | ||
|
Declaration of Voting Results & Voting Rights Announcements
2025年年度股东会决议公告
|
May 28 | ||
|
Share Issue/Capital Change
关于向激励对象预留授予限制性股票的公告
|
May 28 | ||
|
Regulatory Filings
北京市竞天公诚律师事务所上海分所关于睿智医药科技股份有限公司2025年限制性股票激励计划预留授予事项之法律意见书
|
May 28 | ||
|
Share Issue/Capital Change
董事会薪酬与考核委员会关于公司2025年限制性股票激励计划预留授予激励对象名单（授予日）的核查意见
|
May 28 | ||
|
Regulatory Filings
2025年年度股东会法律意见书
|
May 28 | ||
|
Share Issue/Capital Change
2025年限制性股票激励计划预留授予激励对象名单（授予日）
|
May 28 | ||
|
Regulatory Filings
Dokonanie odpisu aktualizującego wycenę kontraktu długoterminowego. - Content (PL)
|
May 28 | ||
|
Regulatory Filings
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
|
May 28 | ||
|
Transaction in Own Shares
Next Day Disclosure Return
|
May 28 | ||
|
Regulatory Filings
INSIDE INFORMATION ANNOUNCEMENT
VISEPEGENATIDE INJECTION INCLUDED IN THE PUBLICATION OF
SUPPLEMENTAL DRUG INFORMATION FOR THE SECOND BATCH OF
REFERENCE DRUG PRE-COMMUNICATION IN 2026
|
May 28 | ||
|
Proxy Solicitation & Information Statement
PROXY FORM
|
May 28 | ||
|
Proxy Solicitation & Information Statement
NOTICE OF ANNUAL GENERAL MEETING
|
May 28 | ||
|
Proxy Solicitation & Information Statement
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND BUY BACK SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED RE-APPOINTMENT OF AUDITOR, PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF
|
May 28 |
%20Inc./other/ImmuneOnco_Biopharmaceuticals_Shangh_dua8aBf.png)
Companies in this industry
| Company | Country | Market cap |
|---|---|---|
1NKEMIA
Biotechnology company providing R&D and services for the life sciences sector.
|
Spain | — |
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
|
Sweden | $5.24M |
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis technologies and health solutions.
|
Canada | — |
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
|
Sweden | — |
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
|
South Korea | — |
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
|
South Korea | — |
%20Corporation/other/Abnova_Taiwan_Corporation-logo.png){kind=logo}
Abnova
Global leader in high-throughput production of antibodies and recombinant proteins.
|
Taiwan | $40.26M |
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
|
United States of America | $1.42M |
Absci Corp
A generative AI drug creation company developing biologic medicines.
|
United States of America | $762.38M |
Achiko AG
A digital services platform for cross-border business compliance and engagement.
|
Switzerland | — |
ACROBIOSYSTEMS CO.,LTD.
Provides recombinant proteins and reagents for life sciences and drug development.
|
China | — |
ACTINOGEN MEDICAL LIMITED
Developing cortisol-inhibiting therapies for Alzheimer's and cognitive impairment.
|
Australia | — |
Active Biotech
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
|
Sweden | $19.24M |
Adagene Inc.
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
|
Cayman Islands | $188.05M |
ADALTA LIMITED
Clinical-stage biotech developing i-body protein therapeutics for fibrotic diseases.
|
Australia | — |
Adaptive Biotechnologies Corp
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
|
United States of America | $2.22B |
Adeia Inc.
R&D company that licenses IP for the media, entertainment, and semiconductor industries.
|
United States of America | $2.91B |
Aditxt, Inc.
Acquires, develops, and deploys health technologies to address major health challenges.
|
United States of America | $47k |
Advanced Biomed Inc.
Develops microfluidic biochip diagnostic systems for precision oncology.
|
United States of America | $6.51M |
Advanced Proteome Therapeutics Corporation
Develops proprietary technology for chemical modification of proteins to create anti-cancer ADCs.
|
Canada | — |
AIM ImmunoTech Inc.
Immuno-pharma company developing therapeutics for oncology, immune, and viral diseases.
|
United States of America | $2.32M |
Ainos, Inc.
Develops AI-driven diagnostics, immune therapeutics, and telehealth POCT devices.
|
United States of America | $10.75M |
Akela Pharma Inc.
Integrated drug developer focused on pain and inhalation, prioritizing contract services.
|
Canada | — |
Akero Therapeutics, Inc.
Clinical-stage company developing treatments for serious metabolic diseases like MASH.
|
United States of America | $4.50B |
Aladdin Healthcare Technologies SE
Develops AI-powered tools for drug discovery and diagnostics for age-related conditions.
|
Germany | — |
Alamar Biosciences, Inc.
Powering precision proteomics for earliest disease detection with ultra-high sensitivity platform.
|
United States of America | — |
Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.
|
United States of America | $5.73M |
ALGORAE PHARMACEUTICALS LIMITED
Biopharmaceutical firm using AI to develop neurodegenerative disease treatments.
|
Australia | — |
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing therapeutics for liver and viral diseases.
|
United States of America | $42.51M |
Allelix Biopharmaceuticals Inc.
Biopharmaceutical R&D focused on protein-based drugs and neuroscience therapeutics.
|
Canada | — |
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
|
United States of America | $916.18M |
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
|
South Korea | — |
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for neurodegenerative disorders.
|
Australia | — |
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
|
Sweden | $21.28M |
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors and fibrotic diseases.
|
Australia | — |
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
|
United States of America | $1.76B |
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions for humans and animals.
|
Australia | — |
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
|
South Korea | — |
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE studies, and drug development.
|
China | — |
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
|
United States of America | $91.53M |
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
|
United States of America | $91.47M |
AnorMED Inc.
Developed small molecule therapeutics for serious diseases, including cancer and HIV.
|
Canada | — |
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-ion battery applications.
|
Australia | — |
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, development, and manufacturing.
|
India | — |
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
|
United States of America | $7.26M |
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
|
United States of America | $7.82M |
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
|
South Korea | — |
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
|
Sweden | — |
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics, and therapeutics.
|
United Kingdom | $27.66M |
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
|
United States of America | $5.73M |